The Fully Human Therapeutic Monoclonal Antibody Platform (HuMAb)

1. Antibodies = immune defense and therapeutic breakthrough!
2. The Structure of Antibodies
3. Generating Therapeutic Antibodies for Clinical Application
4. Key Strategic Choices
5. Competitive Advantage
6. Biological Validation as a Critical Step for Product Selection
7. Business Model
8. NovImmune’s pipeline for Therapeutic Monoclonal Antibodies

SCIENTIFIC PLATFORMS: HuMAb
7. Business Model

NovImmune is developing its therapeutic antibodies all the way to IND filing, Phase I and Phase II clinical trials.

This step is chosen deliberately from the point of view of cost versus value. NovImmune is then in a position to choose among two possibilities:

  • Licensing out the drug to a pharma company after successful Phase II trials (for all or for selected indications)
  • Co-development with a pharma company (for all or for selected indications).
In addition, NovImmune intends to offer selected MAb projects from its pipeline as co-development or licensing opportunities to pharma or biotech partners. Finally, NovImmune also retains the option of keeping selected orphan drug indications for inhouse development beyond Phase II clinical trials.
© Novimmune 2008